# A Study to Evaluate the Safety and Efficacy of Lotemax Ophthalmic Suspension 0.5%

> **NCT01437982** · PHASE4 · COMPLETED · sponsor: **Bausch & Lomb Incorporated** · enrollment: 140 (estimated)

## Conditions studied

- Conjunctivitis, Seasonal Allergic
- Conjunctivitis, Giant Papillary
- Inflammation

## Interventions

- **DRUG:** Loteprednol Etabonate
- **DRUG:** Prednisolone Acetate 1% Oph Susp

## Key facts

- **NCT ID:** NCT01437982
- **Lead sponsor:** Bausch & Lomb Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-08-05
- **Primary completion:** 2015-10-19
- **Final completion:** 2015-10-19
- **Target enrollment:** 140 (ESTIMATED)
- **Last updated:** 2019-11-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01437982

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01437982, "A Study to Evaluate the Safety and Efficacy of Lotemax Ophthalmic Suspension 0.5%". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01437982. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*